Saturday 7 November 2026 Export TRIB’s income statement to Excel — free account

Trinity Biotech PLC

Trinity Biotech PLC’s revenue for fiscal 2025 (year ended December 2025) was $43.8 million, down 28.9% from fiscal 2024.

Revenue: +43.3%
EPS: +52.1%
Free cash flow: +75.2%
Total debt: +29.9%

Quarter to March 2026, against a year earlier

Dividend growth 5 yrs

6.07 0.17 +2.88%

Follow TRIB

Alert me

Market cap: $3.8M
P/E: 0.0×
Fwd P/E: −1.3×
Dividend yield: —
F-score: 4/9
Altman Z: −2.78
Beneish M: −4.29
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 1.77%

Capital & Financial Ratios $m

Size

Market Cap 3.77

Revenue ttm 47.06

Net income ttm (32.97)

Free cash flow ttm (4.28)

Net debt Q 135.05

Valuation

P/E 0.00

Forward P/E (1.33)

Price / sales 0.08

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.00

Financial health

Current ratio Q 0.22

Debt / equity Q (1.81)

Interest coverage Q (1.51)

Growth

Revenue growth Q +43.28%

Operating income growth Q +58.97%

EPS, this year −0.60%

EPS, next year A +38.42%

Revenue, next year A +77.00%

EPS, past 5 yrs —

EPS, next 5 yrs A +53.32%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.18%

10-year low 10-year high

EV/Sales against its own 10 years 90.58%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	4	5	5	2
Receivables	14	16	11	11
Inventory	20	19	19	18
Other	2	1	0	1
	39	41	36	31

	2023	2024	2025	Q'26
Payables	13	27	30	30
ST’ Debt	—	—	108	110
Other	0	3	1	1
	15	32	141	144

Compound Annual Growth %

	10y	5y	3y
Sales	(7.94%)	(15.56%)	(11.20%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Earnings Trends EPS, adjusted, against the consensus

Sep 2024 Estimate −16.22 Actual −12.91

−30.18 −23.35 −16.52 −9.69 −2.86

Sep 2022 Miss −21.02

Dec 2022 Miss −18.02

Jun 2024 Beat +3.00

Sep 2024 Beat +3.31

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Sep 2022	−6.01	−27.03	Miss by 21.02
Dec 2022	−9.01	−27.03	Miss by 18.02
Jun 2024	−19.52	−16.52	Beat by 3.00
Sep 2024	−16.22	−12.91	Beat by 3.31

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(6.90)	—	—	—	—
’25	(14.40)	(9.60)	(8.40)	(27.00)	(60.00)
’24	(11.10)	(21.30)	(13.80)	(28.32)	(53.10)
’23	(22.50)	(24.00)	(27.00)	(21.60)	(94.20)
’22	(75.00)	(43.50)	(36.00)	(39.00)	(183.00)
’21	10.61	(6.00)	13.50	(9.00)	6.00
’20	(6.00)	(8.49)	48.00	(46.50)	(46.50)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	11	—	—	—	—
’25	8	11	14	11	44
’24	15	16	15	16	62
’23	15	14	15	13	57
’22	16	15	16	16	63
’21	26	26	22	20	93
’20	21	16	32	33	102

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	—	—	—	—
’25	(3)	(2)	0	(1)	(6)
’24	(3)	(1)	(4)	3	(4)
’23	(3)	(4)	(5)	0	(12)
’22	(1)	(2)	1	2	(1)
’21	6	1	2	4	13
’20	2	3	7	12	24

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	—	—	—	—
’25	(5)	(6)	(1)	(2)	(12)
’24	(4)	(4)	(6)	1	(14)
’23	(3)	(5)	(5)	(1)	(14)
’22	(3)	(4)	(1)	1	(7)
’21	4	(1)	0	2	5
’20	(1)	1	5	9	14

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Mar ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	100	99	97	90	102	93	63	57	62	44	47		(8.7%)	78	—	—	+77.0%
	Gross margin, %	43.65	42.25	42.72	42.15	47.64	40.96	27.62	34.22	34.83	38.57	39.99		(5.1) pt	Powerpack Trinity Biotech PLC’s next three years, line by line Analysts expect revenue to grow 77.0% a year to 2028 — faster than the −8.7% of the last 9 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(42)	(40)	(23)	(30)	(7)	1	(44)	(37)	(31)	(37)	(33)		(1.4%)
	EBT margin, %	(42.30)	(40.22)	(23.89)	(33.17)	(6.50)	0.81	(70.02)	(64.98)	(49.92)	(84.91)	(69.70)		(42.6) pt
	Net income	(101)	(40)	(22)	(29)	(6)	1	(41)	(24)	(32)	(37)	(33)		(10.4%)
Per share, $
Per share, $	Revenue	651.48	688.47	697.09	648.28	732.61	638.06	278.24	222.96	102.92	70.78	74.56		(21.9%)
	Earnings	(657.00)	(279.00)	(159.00)	(207.00)	(46.50)	6.00	(183.00)	(94.20)	(53.10)	(60.00)	(51.90)		(23.4%)
	Cash flow	66.89	64.24	51.93	38.83	170.65	90.86	(4.10)	(45.34)	(7.01)	(9.58)	(6.67)		n/m
	Capex	(135.79)	(104.64)	(124.94)	(84.97)	(73.26)	(59.65)	(26.60)	(10.61)	(16.83)	(10.06)	(0.12)		(25.1%)
	Free cash flow	(68.90)	(40.40)	(73.00)	(46.14)	97.39	31.21	(30.70)	(55.95)	(23.83)	(19.64)	(6.78)		(13.0%)
	Book value	711.10	452.75	316.48	33.78	(15.94)	(2.19)	(9.68)	(93.95)	(58.82)	(116.36)	(119.97)		n/m
	Shares, m	0	0	0	0	0	0	0	0	1	1	1		+16.8%
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	20.43	0.00	0.00	0.00	0.00	0.00		2.0
	P/S	1.60	1.13	0.49	0.24	0.78	0.34	0.57	0.30	0.26	0.34	0.08		0.6
	P/B	1.47	1.72	1.09	4.59	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.9
	EV/Sales	1.76	1.49	1.02	1.19	1.51	1.12	1.62	1.42	1.80	3.31	2.95		1.6
	EV/FCF	(2.57)	(2.41)	(1.76)	(2.49)	(9.45)	(42.78)	(14.69)	(5.64)	(7.77)	(10.28)	(11.25)		(10.0)
Cash, $m
Cash, $m	Operating cash flow	10	9	7	5	24	13	(1)	(12)	(4)	(6)	(4)		n/m
	Capex	(21)	(15)	(17)	(12)	(10)	(9)	(6)	(3)	(10)	(6)	0		(12.5%)
	Free cash flow	(11)	(6)	(10)	(6)	14	5	(7)	(14)	(14)	(12)	(4)		+1.6%
Balance, $m
Balance, $m	Working capital	108	91	69	52	56	(28)	29	24	9	(105)	(112)		n/m
	Net debt	16	36	52	86	74	73	66	62	93	130	135		+26.1%
	Shareholders’ equity	109	65	44	5	(2)	0	(2)	(24)	(35)	(72)	(76)		n/m
Returns, %
Returns, %	ROA	(32.82)	(18.20)	(12.82)	(20.45)	(4.89)	0.70	(38.87)	(31.70)	(39.07)	(35.86)	(32.70)		(3.0) pt
	ROIC	(19.95)	(23.21)	(13.15)	(16.66)	0.07	5.68	(19.06)	(44.62)	(22.84)	(16.99)	(12.61)		+3.0 pt
	ROE	(62.38)	(46.31)	(40.44)	(118.58)	(512.27)	(68.95)	3,287.29	183.87	107.52	69.76	55.26		+132.1 pt
People
People	Employees	582	556	575	579	543	477	398	380	401	287	—		(7.6%)
	Revenue/emp, $m	0.17	0.18	0.17	0.16	0.19	0.19	0.16	0.15	0.15	0.15	—		(1.3%)

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
VNRX VolitionRX Limited	$5.3M	— (loss-making)	— (loss-making)	−1.97% (below 0%: shrinking)	n/m	+18.58% (above 0%: growing)	100.00%	(1,042.39%)	Compare
BDMD Baird Medical Investment Holdings Limited	$5.0M	— (loss-making)	—	—	n/m	−598.12% (below 0%: shrinking)	—	—	Compare
NVNO enVVeno Medical Corporation	$4.8M	— (loss-making)	— (loss-making)	+0.32% (above 0%: growing)	n/m	+27.64% (above 0%: growing)	0.00%	0.00%	Compare
TNON Tenon Medical, Inc.	$4.4M	— (loss-making)	— (loss-making)	+126.77% (above 0%: growing)	n/m	−21.78% (below 0%: shrinking)	63.64%	(262.24%)	Compare
WOK WORK Medical Technology Group LTD	$4.1M	—	—	—	—	−948.94% (below 0%: shrinking)	—	—	Compare
TRIB Trinity Biotech PLC	$3.8M	— (loss-making)	— (loss-making)	+43.28% (above 0%: growing)	n/m	+75.24% (above 0%: growing)	35.43%	(24.53%)
XAIR Beyond Air, Inc.	$3.6M	— (loss-making)	— (loss-making)	+0.45% (above 0%: growing)	n/m	−9.10% (below 0%: shrinking)	12.73%	(373.98%)	Compare
VVOS Vivos Therapeutics, Inc.	$3.5M	— (loss-making)	— (loss-making)	+34.90% (above 0%: growing)	n/m	+16.44% (above 0%: growing)	57.31%	(93.63%)	Compare
AMIX Autonomix Medical, Inc.	$3.0M	— (loss-making)	—	—	n/m	−36.10% (below 0%: shrinking)	—	0.00%	Compare
Median of peers	$4.3M	—	—	+0.45%	—	−15.44%	57.31%	(177.93%)

All 149 Medical Devices stocks →

Trinity Biotech PLC (TRIB) Latest News

9 Sep

Impact 3 · 8:30 AM

Trinity Biotech’s Trinovium Subsidiary Signs Contract to Supply Red Team Investments with Advanced Liquid Cooling Solutions for AI Data Center Infrastructure

28 Aug

Impact 4 · 5:15 PM

Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update

14 Aug

Impact 4 · 9:32 AM

Trinity Biotech Secures Additional $7.0 Million Investment from Perceptive Advisors and Regains Compliance with Nasdaq Minimum Bid Price Requirement

22 Jul

Impact 4 · 7:30 AM

Trinity Biotech Partners with Latch Medical to Advance Biosensor-Guided Precision Drug Delivery Solutions Using CGM+ Technology

2 Jul

Impact 4 · 8:30 AM

New Trinity Biotech Clinical Trial Data Shows Its CGM+ Technology Tackles a Major CGM User Problem by Going Beyond Glucose-Only Monitoring

30 Jun

Impact 3 · 9:00 AM

Trinity Biotech’s Trinovium Secures Open Compute Project Membership, Advancing Hyperscale Market Access and Commercial Validation for AI Data Center Liquid Cooling

23 Jun

Impact 4 · 7:30 AM · GlobeNewswire

Trinity Biotech Launches Trinovium to Bring Healthcare-Grade Fluid Technology to the Rapidly Growing Multi-Billion Dollar AI Data Center Liquid Cooling Market

16 Jun

Impact 4 · 9:10 AM

Trinity Biotech Awarded Significant Orders for Over 2 Million TrinScreen HIV Tests And Reports Q1 2026 Financial Results

1 May

Impact 3 · 9:27 AM · GlobeNewswire

Trinity Biotech Appoints Jerry Lydon to Lead North America Commercial Operations

23 Mar

Impact 4 · 9:23 AM · GlobeNewswire

Trinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture™ Prostate Cancer Test

18 Mar

Impact 4 · 8:30 AM · GlobeNewswire

Trinity Biotech Announces Collaboration with University at Buffalo to Commercialize Novel Biomarkers for Sjögren’s Syndrome

12 Mar

Impact 4 · 9:00 AM · GlobeNewswire

Trinity Biotech Begins Rollout of Innovative Glucose Monitoring System In Key Market Following Regulatory Approval of Next-Generation Premier Hb9210 HbA1c Column System

11 Mar

Impact 3 · 9:00 AM · GlobeNewswire

Trinity Biotech Senior Executives to Attend ATTD 2026 to Advance Collaborations Following Strong Progress in CGM Program

10 Mar

Impact 4 · 7:55 AM · GlobeNewswire

Trinity Biotech Announces Further Major Technical Breakthroughs in Advancing Next Generation CGM+ Platform

Impact 3 · 7:45 AM · GlobeNewswire

Trinity Biotech Provides Business and Trading Update

25 Feb

Impact 4 · 9:00 AM

Trinity Biotech Secures $25 Million Financing Commitment to Support Growth Initiatives

20 Feb

Impact 4 · 5:00 PM · GlobeNewswire

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares

13 Feb

Impact 3 · 5:00 PM · GlobeNewswire

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Nasdaq Minimum Bid Price Requirement

10 Feb

Impact 4 · 1:28 PM · GlobeNewswire

Trinity Biotech Secures Regulatory Approval for Commencement of Upstream Manufacturing Activities of Uni-Gold™ HIV Rapid Test Under Its Offshored and Outsourced Model, Supporting Financial Performance Transformation

Impact 4 · 8:00 AM · GlobeNewswireExec EdgeMedical Device NetworkPharmaceutical TechnologyMedical Device NetworkClinical Trials ArenaMedical Device NetworkBarchart

Trinity Biotech Glucose Monitoring Innovation Achieves Unique Global Recognition: Diabetes Care Premier Hb9210™ HbA1c Analyser Becomes the Only System Awarded Prestigious IFCC Gold Classification for 2026

2 Feb

Impact 3 · 11:09 AM

European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading

24 Dec

Impact 3 · 11:14 AM · MT Newswires

European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading

23 Dec

Impact 4 · 11:45 AM

Trinity Biotech Stock Jumps 60% After Major Breakthrough

Impact 4 · 8:50 AM · GlobeNewswire

Trinity Biotech Announces Agreements to Strengthen Capital Structure and Support Growth Initiatives

Impact 4 · 7:32 AM · GlobeNewswireGuruFocus.comInsider MonkeyZacksGuruFocus.comGuruFocus.comMotley FoolGuruFocus.com

Trinity Biotech Awarded a Major Order for 9 Million TrinScreen HIV Tests

Impact 3 · 12:13 PM · MT Newswires

European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading

22 Dec

Impact 3 · 11:12 AM · MT Newswires

European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading

17 Dec

Impact 3 · 11:10 AM

European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading

15 Dec

Impact 4 · 9:15 AM

Trinity Biotech Expands Global Rollout of High-Capacity Column System for FDA-Cleared HbA1c Testing Solution After Securing Regulatory Clearances

1 Dec

Impact 3 · 11:02 AM · MT Newswires

European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Trinity Biotech PLC vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Trinity Biotech PLC (TRIB) Latest News

9 Sep

28 Aug

14 Aug

22 Jul

2 Jul

30 Jun

23 Jun

16 Jun

1 May

23 Mar

18 Mar

12 Mar

11 Mar

10 Mar

25 Feb

20 Feb

13 Feb

10 Feb

2 Feb

24 Dec

23 Dec

22 Dec

17 Dec

15 Dec

1 Dec

Stockrow Weekly